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Structure-based drug discovery 
for combating influenza virus by 
targeting the PA–PB1 interaction
Ken Watanabe1, Takeshi Ishikawa  1, Hiroki Otaki  1, Satoshi Mizuta1, Tsuyoshi Hamada2, 
Takehiro Nakagaki1, Daisuke Ishibashi1, Shuzo Urata3, Jiro Yasuda3, Yoshimasa Tanaka1 & 
Noriyuki Nishida1,2
Influenza virus infections are serious public health concerns throughout the world. The development of 
compounds with novel mechanisms of action is urgently required due to the emergence of viruses with 
resistance to the currently-approved anti-influenza viral drugs. We performed in silico screening using 
a structure-based drug discovery algorithm called Nagasaki University Docking Engine (NUDE), which 
is optimised for a GPU-based supercomputer (DEstination for Gpu Intensive MAchine; DEGIMA), by 
targeting influenza viral PA protein. The compounds selected by NUDE were tested for anti-influenza 
virus activity using a cell-based assay. The most potent compound, designated as PA-49, is a medium-
sized quinolinone derivative bearing a tetrazole moiety, and it inhibited the replication of influenza 
virus A/WSN/33 at a half maximal inhibitory concentration of 0.47 μM. PA-49 has the ability to bind PA 
and its anti-influenza activity was promising against various influenza strains, including a clinical isolate 
of A(H1N1)pdm09 and type B viruses. The docking simulation suggested that PA-49 interrupts the PA–
PB1 interface where important amino acids are mostly conserved in the virus strains tested, suggesting 
the strain independent utility. Because our NUDE/DEGIMA system is rapid and efficient, it may help 
effective drug discovery against the influenza virus and other emerging viruses.
Influenza is caused by acute influenza virus infection. Influenza pandemics occur due to antigenic shifts in 
the virus and they have caused significant morbidity and mortality in humans. At present, two classes of 
anti-influenza viral medicines have been approved: M2 inhibitors (amantadine and rimantadine) and neurami-
nidase (NA) inhibitors, such as, oseltamivir1. However, influenza viruses have mutated to become resistant to 
these inhibitors, thereby reducing their efficacy2. For example, oseltamivir-resistant seasonal H1N1 virus spread 
worldwide very rapidly during the 2007/2008 influenza season3–5. To avoid emergence of drug-resistant viruses, 
the combined use of antiviral drugs with different mechanisms of action is a good strategy as has been reported 
in the treatment of human immunodeficiency virus (HIV)-1. Therefore, the development of anti-influenza viral 
drugs with novel mechanism of action is needed.
Influenza A and B viruses are enveloped, negative-stranded RNA viruses with eight-segmented genomes. 
The influenza virus life cycle initiates by binding to the cell surface via hemagglutinin (HA), which is followed by 
fusion of the viral membrane and endosome. The viral ribonucleoprotein complex (vRNP) will be released into 
the cytoplasm by function of M2 protein of the virus. vRNP comprises viral RNA (vRNA), nucleoprotein (NP) 
and the three subunits of viral RNA-dependent RNA polymerase (RdRp): PB1, PB2 and PA. vRNP is transported 
to the nucleus and early transcription and replication from vRNP occur with the assistance of host factors6, 7. 
The progeny vRNP is exported from the nucleus into the cytoplasm8, 9. Viral assembly and budding occur on the 
plasma membrane with the progeny vRNP and newly synthesised late proteins such as HA, NA, M1, M2 and NS2.
Among the 10 viral-encoded proteins, RdRp could be a good target for the development of new drugs10 
because RdRp does not exist in mammals and is essential for replication. In addition, the amino acid residues in 
each RdRp subunit (PB1, PB2 and PA) are highly conserved among type A viruses. Of the three RdRp subunits, 
PB1 and PB2 are responsible for viral RNA synthesis and binding to the cap structure of cellular-capped RNA 
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(required for the initiation of viral transcription), respectively, whereas PA has multiple roles, such as cleav-
age of the capped RNA11 and serine proteinase activities12. Lack of PA protein expression in a reverse genetics 
system led to no recovery of recombinant influenza virus13, thereby suggesting that PA has crucial roles in the 
virus life cycle14. PA interacts with PB1 and PB1 interacts with PB2 according to crystal structure analyses15–17. 
The C-terminus of PA (residues 239–716) interacts with the N-terminus (residues 1–25) of PB1. According to 
this model, the binding between PA and PB1 involves hydrogen bonds and hydrophobic contacts, where the 
N-terminal residues of PB1 are inserted in the pocket of PA15. To explore PA-targeting inhibitors, various tech-
niques such as NMR method18, phylogenetic analysis19 and high-throughput ELISA-based screening20, 21 have 
been reported.
The crystal structure information accumulated for various proteins allows us to design new antivirals by 
structure-based drug design (SBDD). SBDD has been used widely for the development of antiviral drugs, such 
as the HIV-1 proteinase inhibitor, nelfinavir22 and influenza viral NA inhibitor zanamivir23. Recent advances in 
SBDD have largely been made due to the development of computer system and docking simulation software. 
To facilitate the identification of novel drugs, we recently developed the Nagasaki University Docking Engine 
(NUDE) which efficiently runs on the DEstination for Gpu Intensive MAchine (DEGIMA) supercomputer. Using 
this system, we have succeeded in development of anti-prion compounds24 and anti-influenza virus compounds 
that target influenza viral NP25. In the present study, we performed in silico screening of approximately 600,000 
molecular structures with NUDE to identify compounds that can bind the pocket in PA bound by PB1. We found 
that a quinolinone derivative bearing a tetrazole moiety effectively suppressed the replication of influenza viruses.
Results
In silico and in vitro screening of anti-influenza virus compounds. To obtain potent anti-influenza 
compounds we targeted the influenza viral polymerase subunit PA–PB1 interaction, which is essential for the 
viral life cycle15. Approximately 600,000 compounds in the chemical compound library were ranked based on the 
docking score obtained by the NUDE, and the top 136 compounds designated as PA-1 to PA-136 were selected as 
candidates of anti-influenza compounds. Among these compounds, 99 commercially available compounds were 
purchased and then subjected to cell-based screening using crystal violet (CV) assays, which reflected the virus 
infection-induced cytopathic effects (CPE) in cells (Supplementary Fig. S1). In this assay, when cells were infected 
with the virus, the cells detached from the bottom of the dish due to the appearance of CPE. We performed 
this assay using serially diluted compounds. The morphology of cells was observed under a microscope and the 
minimum inhibitory concentration (MIC) was estimated visually after CV staining. Fig. 1 summarises the struc-
tures of 14 compounds with MIC values less than 20 μM, where 11/14 compounds were quinolinone derivatives 
bearing a tetrazole moiety (Fig. 1a). PA-49 (ranking = 49th, docking score = −336.77) had the best MIC value of 
1.7 μM but no significant cytotoxicity (Supplementary Fig. S2). Therefore, PA-49 was selected as representative of 
the quinolinone derivatives. Other different compounds (Fig. 1b) were also selected for further experiments (a 
4-aza-9-fluorenone derivative (PA-37, MIC value = 1.7 μM, ranking = 37th, docking score = −339.311), tetracy-
clic compound (PA-58, MIC value = 16.6 μM, ranking = 58th, docking score = −336.051), and 8-azahypoxanthin 
derivative (PA-107, MIC value = 16.6 μM, ranking = 107th, docking score = −331.554)). These results suggest that 
our in silico programme, NUDE24, is a very useful tool for screening hit compounds.
Evaluating the binding between hit compounds and PA protein using surface plasmon reso-
nance (SPR) analysis. SPR analyses were performed to analyse the binding affinities of the hit compounds 
Figure 1. Hit compounds with anti-influenza virus activity. Hit compounds selected by in silico screening were 
tested to determine their anti-influenza virus activities via cell-based screening. Potent compounds with anti-
influenza virus activities (MIC value < 20 μM) are shown. (a) Compounds bearing quinolinone and tetrazole 
moieties. (b) Compounds containing different scaffolds.
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with PA protein (Fig. 2). Anti-PA antibody was immobilised on the sensor chip, and then captured approx-
imately 2000 RU of the purified recombinant PA protein (residues 239–716). Signals obtained from the sen-
sor chip-immobilised anti-PA antibody alone were subtracted as the background. Benzbromarone, a uricosuric 
agent, has been reported to bind the PB1-binding pocket of PA26, so we used benzbromarone as a positive control. 
In the presence of the compound the binding response was observed in a dose-dependent manner, suggesting 
that recombinant PA protein was suitable for evaluating the SPR analyses. PA-37, 49, 58 and 107 bound to PA 
protein in a dose-dependent manner (Fig. 2a). Using a 1:1 binding model, the dissociation constant (KD) was 
calculated from the fitting curve (Fig. 2b). The hit compounds had various KD values (Table 1). PA-37 differed in 
terms of the MIC and KD values, which suggests that PA-37 may have a target other than PA. PA-58 had good KD 
values but significant toxicity (Supplementary Fig. S1). The binding affinity of PA-107 to PA was relatively weak. 
By contrast, PA-49 was the most potent compound with good MIC and KD values of 1.7 μM and 7.5 μM, respec-
tively. Therefore, we selected PA-49 for further analyses.
PA-49 suppresses nuclear accumulation of PA. We performed a nuclear transportation-inhibition 
assay to confirm whether subcellular localisation of PA changes in the presence of PA-49 or not (Fig. 3 and 
Supplementary Fig. S3). It has been reported that the PB1 subunit is required for efficient nuclear accumulation 
of the PA subunit27. In Fig. 3, the experiment showed that in the absence of PA-49, PA dominantly localised in the 
nucleus where PB1 exists, and addition of PA-49 to PA- and PB1- cotransfected cells did change localisation of PA 
to the cytoplasm. These results suggest that PA-49 interfere with the PA–PB1 interaction.
Figure 2. Direct binding between PA protein and hit compounds. Compounds selected by cell-based screening 
were subjected to surface plasmon resonance analysis. Anti-PA antibody was immobilised on the sensor chip 
and captured the recombinant PA protein before various concentrations of compounds were loaded as analytes. 
(a) Sensorgram and (b) fitting curves from the sensorgram were shown.
compound
Cell-based 
screening PA binding Plaque inhibition 
assay IC50 (μM)cMIC (μM)a KD (μM)b
PA-37 1.7 74.4 ± 27.0 N.D.d
PA-49 1.7 7.5 ± 2.0 0.47 ± 0.13
PA-58 16.6 13.6 ± 5.5 N.D.
PA-107 16.6 105 ± 24.8 N.D.
Table 1. Summary of anti-influenza viral activity of hit compounds. aMIC; minimum inhibitory concentration. 
bObtained from three independent SPR analyses using recombinant PA. cIC50; half maximal inhibitory 
concentration. dNot determined.
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PA-49 suppresses influenza virus propagation. We performed screening to select anti-influenza com-
pounds based on CV assays (Supplementary Fig. S1) because CV staining is an alternative and rapid method for 
evaluating cytotoxicity and antiviral activities28, 29. To confirm the correlations between the CV assays and antivi-
ral activities, we compared the antiviral activity of PA-49 based on cell morphology, water-soluble tetrazolium salt 
(WST-1), CV staining and 50% tissue culture infective dose (TCID50) assays (Fig. 4). When Madin–Darby canine 
kidney (MDCK) cells were infected with the influenza virus without PA-49, the cells detached from the bottom 
of the well (Fig. 4a, panel E). In the presence of 0.5 μM PA-49, the cells were partially attached (panel F), and the 
cell condition among the infected cells treated with 0.8 and 2 μM PA-49 are almost the same with uninfected 
control (panel A). The viral titre in the supernatant (Fig. 4b) was dose-dependent and it decreased dramatically 
(2.2 × 104 TCID50/mL) by nearly 1/1000th compared to the control after treatment with 2 μM PA-49 where the cell 
viability was good according to WST-1 measurements. The viral titres in the presence of 20 and 100 μM oseltam-
ivir were measured as controls that were 2.1 × 105 ± 1.5 × 105 and 2.7 × 105 ± 0.7 × 105 TCID50/mL, respectively 
(Supplementary Fig. S4). These results suggest that PA-49 has potent antiviral activity. The viral titre appeared 
to be highly correlated with the relative optical density (OD) values determined in the CV assays. Therefore, we 
decided to use the CV assays for further evaluations of the 50% effective concentration (EC50) values.
Determination of IC50 by plaque inhibition assay. Determining EC50 values using the CV assay is a 
feasible and rapid method for evaluating many samples. We also evaluated the antiviral activity of PA-49 using 
a plaque inhibition assay, which is the gold standard method for evaluating antiviral activity30, in order to deter-
mine whether plaque formation in MDCK cells was suppressed by PA-49 treatment. MDCK cells in six-well 
plates were infected with approximately 200 plaque-forming units (pfu) of virus and the cells were then over-
laid with agarose solution containing various amounts of PA-49. The number of plaques formed decreased in a 
dose-dependent manner (Fig. 5a and b), where the 50% inhibitory concentration (IC50) determined by the plaque 
inhibition assay was 0.47 ± 0.13 μM (Table 1). These results suggest that PA-49 effectively suppressed influenza 
virus propagation in the cell culture.
PA-49 suppresses the expression of viral proteins. The formation of the PA–PB1 complex is essential 
for obtaining a functional vRNP complex. In this study, we targeted the PB1-binding pocket of PA. Viral tran-
scription/replication from the newly synthesized vRNP complex might not occur in the presence of PA-49. Thus, 
western blotting was performed to confirm the expression of viral proteins (Fig. 6). MDCK cells were infected 
at a multiplicity of infection (MOI) of 1 before adding increasing concentrations (0.5–20 μM) of PA-49. At 9 h 
post-infection (hpi), the control uninfected MDCK cells were attached tightly to the dish (Fig. 6a, mock no 
drug). The cell morphology and viability was not affected by the presence of different concentrations of PA-49 
(0.5–20 μM), indicating the low toxicity of PA-49 (Supplementary Figs 5a and 6). The cells were recovered and 
Figure 3. Effect of PA-49 on subcellular localisation of PA protein. In 24-well plates, HeLa cells were 
seeded on coverslips and grown to 70–80% confluence. Cells were then transfected with 0.5 μg of plasmid as 
indicated then 3.5 h after transfection, PA-49 was added then incubated further 25.5 h. Cells were fixed with 
4% paraformaldehyde for 10 min, and were permeabilised by 0.1% NP40 in PBS for 20 min. The cells were 
incubated with 1% skim milk in PBS for 40 min. The cells were then reacted with anti-PA or -PB1 antibody. 
After washing, the cells were reacted with Alexa Flour 488-conjugated anti-rabbit IgG (Thermo Fisher Scientific 
K.K., Kanagawa Japan; A11008). (a) Subcellular localisation of PA and PB1 in the absence or the presence 
of 40 μM PA-49 were shown. Scale bar; 25 μm. (b) The percentage of cells showing greater nuclear than 
cytoplasmic localisation (N>C), nuclear equal to cytoplasmic localisation (N=C) or cytoplasmic localisation 
(N<C) was determined by direct counting. The mean and standard deviation obtained from three different 
areas were shown.
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Figure 4. Anti-influenza virus activity of PA-49. The anti-influenza virus effects of PA-49 were evaluated as 
described in the Methods section. MDCK cells grown in 24-well plates were infected and treated with serial 
dilutions of PA-49. At 48 h after infection, the cell morphology (a) was observed (scale bar; 150 μm) and (b) 
the antiviral effects on cells were measured by the WST-1 assay (closed circles) or CV staining (open circles). 
Optical density (OD) values (%) are expressed relative to the percentage of cells without virus infection. Viral 
titres in the supernatant (open triangles) were measured by TCID50 assays.
Figure 5. Determination of IC50 values by plaque inhibition assay. (a) Inhibition of plaque formation in the 
presence of PA-49. Confluent MDCK cells seeded in six-well plates (2 × 106 cells/well) were then infected with 
approximately 200 pfu of A/WSN/33 virus at 37 °C for 1 h. After removing the medium, the cells were overlaid with 
4 mL of PA-49-containing agarose solution (0.8% agarose, 0.1% BSA and MEM vitamin) and incubated for 2 days. 
The cells were fixed and stained with 0.5% Amido black. After washing with water and air drying, the number of 
plaques was counted visually. Representative results from three independent experiments are shown. (b) Results of 
plaque formation experiments in (a) and two other experiments are shown as relative plaque numbers.
www.nature.com/scientificreports/
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analysed by western blotting (Fig. 6b and c). At 9 hpi, in the presence of PA-49, the band intensity was reduced in 
a dose-dependent manner. These results suggest that PA-49 suppresses influenza virus replication by inhibiting 
viral RNA synthesis.
PA-49 affects virus replication but not virus particles, cells and adsorption. PA-49 may inhibit 
the formation of viral polymerase PA–PB1 subunit, but PA-49 might also affect other parts of the virus life cycle, 
such as virus attachment or entry into cells. Thus, time-of-addition assays were performed to confirm the mode 
of action for PA-49 (Fig. 7a). The pre-treatment of cells and pre-treatment of virus with 1 and 2 μM PA-49 had 
no effects on the relative plaque numbers, thereby suggesting that PA-49 does not bind to a cellular receptor 
and that it lacks a virucidal activity. However, a significant reduction (over 99%) in the relative plaque number 
was observed when 2 μM of PA-49 was added to the agarose solution (‘in agarose’). Thus, PA-49 had signifi-
cant antiviral activity against influenza virus when replication cycle occurs. These results were also supported by 
RT-PCR analysis (Supplementary Fig. S7). To exclude the possibility that PA-49 inhibits viral binding to the cel-
lular receptor, a hemagglutination inhibition assay was performed using chicken red blood cells (RBCs) (Fig. 7b). 
As expected, hemagglutination occurred when RBCs were mixed with influenza virus (Fig. 7b, no drug), where 
the HA titres for A/WSN/33(H1N1) and A/Aichi/2/68(H3N2) were 320 and 160 HA units/mL, respectively. The 
presence of PA-49 (1–20 μM) did not affect the hemagglutination reaction. These results suggest that PA-49 has 
no effect during the binding/entry step of the infection process.
Antiviral effect of PA-49 on various influenza viruses. Antiviral effect of PA-49 on various influenza 
viruses were tested using the CV assay (Table 2). The EC50 value of oseltamivir against A/WSN/33 was found to 
be similar to that reported previously29. When PA-49 was used in the analysis, the EC50 values against A/Virginia/
Figure 6. PA-49 suppresses the expression of viral proteins. MDCK cells (2 × 105 cells/well) were seeded in 
24-well plates and infected with A/WSN/33 at an MOI of 1 in the absence or presence of PA-49 (0.5–20 μM). 
(a) At 9 hpi, the cells were observed by phase contrast microscopy. Scale bar, 150 μm. (b) At 3 or 9 hpi, the 
cells were then lysed and subjected to 10% SDS-PAGE, and then transferred onto a polyvinylidene fluoride 
membrane. The membrane was incubated with a 1:30,000 dilution of anti-NP or anti-M1, 1:5,000 dilution of 
anti-HA or anti-PA, 1:3,000 dilution of anti-PB1, or 1:150 dilution of anti-actin for 4 h, followed by treatment 
with the biotinylated secondary antibody and streptavidin alkaline phosphatase, and visualisation using BCIP 
and NBP. (c) The band intensity was quantified by Image J software. The expression level of actin was used for 
normalisation. To calculate the relative intensity (%) for 3- and 9-h PA-49-treated samples, the band intensity 
of 9-h- infected cells without PA-49 treatment was shown as 100%. Data represent the means and standard 
deviation from two independent experiments.
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ATCC2/2009, A/WSN/33, A/Puerto Rico/8/34 and A/Aichi/2/68, were similar, ranging from 0.53 to 0.62 μM. 
PA-49 was also effective against B/Lee/40 with an EC50 value of 0.92 μM. The viral titre in the supernatant was 
measured by the HA assay because PA-49 did not affect the hemagglutination of the H1N1 and H3N2 subtypes 
(Fig. 7b). The HA titres in the culture supernatants of A/WSN/33-, A/Puerto Rico/8/34- and A/Aichi/2/68- 
infected cells in the presence of 1 μM PA-49 were <0.8%, <0.8% and <3.1% compared with the no drug control, 
respectively. In addition, the IC50 and EC50 values determined for the A/WSN/33 strain were similar using the 
plaque inhibition and CV assays (compare Tables 1 and 2). We also tested the antiviral activity of PA-49 against 
several negative-stranded RNA viruses that have RdRp including severe fever with thrombocytopenia syndrome 
Figure 7. Mode of action of PA-49. (a) Time-of-addition experiments. Approximately 200 pfu of virus in MEM 
vitamin was used for infection. The detailed procedures for each treatment are as follows. (i) Pre-treatment 
of cells: before the plaque inhibition assays, MDCK cells were pre-treated with the test samples at 37 °C for 
3 h. After removing the medium, cells were washed with MEM and infected by adding the viral suspension in 
MEM vitamin. (ii) Pre-treatment of virus: approximately 107 pfu/mL of virus stock was pre-incubated with 
the test samples on ice for 3 h. The mixture was subsequently diluted in MEM vitamin and 400-μL aliquots 
(200 pfu) of the diluted mixture were used for infection. (iii) Simultaneous: 200-μL aliquots of the test samples 
in MEM vitamin were added to MDCK cells, followed by 200 μL of the virus suspension. The cells were then 
incubated for 1 h. (iv) In agarose: after viral infection for 1 h, the cells were overlaid with 4 mL of agarose 
solution containing the samples and MEM supplemented with 0.8% agarose, 0.1% BSA and 1% 100 × vitamin 
solution. Two days later, the cells were fixed and stained. Relative plaque numbers based on three independent 
experiments are shown. Grey and white bars show the 2 and 1 μM PA-49 treatments, respectively. **Indicates 
p < 0.01; ***indicates p < 0.001. (b) PA-49 does not inhibit the hemagglutination activity of viral HA protein. 
Twofold serial dilutions of A/WSN/33 and A/Aichi/2/68 in PBS, as well as 4, 20 and 80 μM of PA-49 in PBS 
were prepared. In 96-well plates, 25 μL of each serially diluted virus and PA-49 solution were mixed and then 
incubated at 4 °C for 1 h before adding 50 μL of 5% (v/v) chicken RBCs in PBS. Hemagglutination was observed 
after incubating at room temperature for 1 h.
Compound
CC50a 
(μM) Strain Subtype EC50b (μM) SIc
Relative titred (%)
1 μM 10 μM
Oseltamivir >100 A/WSN/33 H1N1 4.0 ± 1.1 >24.8 14.6 ± 9.5 <1.6
PA-49 >100
A/WSN/33 H1N1 0.57 ± 0.02 >175 <0.8 <0.8
A/Puerto Rico/8/34 H1N1 0.53 ± 0.01 >189 <0.8 <0.8
A/Aichi/8/68 H3N2 0.56 ± 0.01 >179 <3.1 <3.1
A/Virginia/ATCC2/2009e H1N1 0.62 ± 0.02 >161 N/Af N/A
B/Lee/40 Type B 0.92 ± 0.07 >109 18.8 ± 8.8 9.4 ± 4.4
Table 2. Efficacy of PA-49 against various strains of influenza virus. aCC50; 50% cytotoxic concentration 
estimated by CV assay. bEC50; 50% effective concentration estimated by CV assay. cSI: selective index = CC50/
EC50. dRelative virus titre in the presence of compound was estimated by HA assay vs no drug control. eClinical 
isolate of A(H1N1)pdm09 virus. fThis strain was not sensitive to chicken RBC.
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virus (SFTSV, Bunyaviridae), Hazara virus (Bunyaviridae), vesicular stomatitis virus (Rhabdoviridae) and lym-
phocytic choriomeningitis virus (Arenaviridae), because these RNA viruses have a similar replication mechanism 
with influenza virus31, 32. RdRp of these viruses is a single polypeptide called L protein, whereas that of influenza 
virus is composed of subunits of PA, PB1 and PB2. As expected, PA-49 did not show significant antiviral activity 
against these RNA viruses (Supplementary Fig. S5b). These results suggest that PA-49 can specifically inhibit the 
replication of influenza viruses types A and B.
Discussion
To explore novel anti-influenza compounds using SBDD, focusing on the PA–PB1 interaction which co-crystal 
structure of PA and PB1 has also been reported15, we screened for compounds that targeted the major pocket in 
PA binding PB1 and inhibits the replication of influenza virus. We expanded our in-house library to approxi-
mately 600,000 compounds, and the top 99 compounds were then subjected to in vitro assays. Among that, the 
activity of PA-49 was promising against various influenza viruses, including types A and B (Table 2). Our plaque 
inhibition and CV assays suggested that PA-49 inhibits viral replication (Fig. 5 and Table 2). At 9 hpi, the expres-
sion levels of late viral proteins M1 and HA, which are synthesised from progeny vRNP, were effectively sup-
pressed compared with those of early viral proteins PA, PB1 and NP, which are synthesised from incoming vRNP. 
PA-49 could suppress the PA–PB1 interaction (Fig. 3) when newly synthesised vRNP assembly occurred, whereas 
the incoming vRNP had already formed the PA–PB1 complex. The effect of PA-49 on the expression levels of viral 
proteins (Fig. 6b) was relatively weak compared with that on the viral titre in the supernatant (Fig. 4b), probably 
because the appropriate ratio of viral proteins must be expressed for efficient virion formation13.
The EC50 values for PA-49 were similar against A/Virginia/ATCC2/2009(H1N1), A/WSN/33(H1N1), A/
Puerto Rico/8/34(H1N1), A/Aichi/2/68(H3N2) and B/Lee/40 (Table 2), which suggests that PA-49 has a broad 
spectrum of anti-influenza virus activities. In general, the amino acid sequence of PA is highly conserved. It 
should be noted that the amino acid residues required to form the hydrogen bonds and hydrophobic contacts 
across the PA–PB1 interface15 are also conserved among various influenza A virus strains, including the H1N1, 
H3N2 and H5N1 subtypes (Fig. 8c). The docking simulation results suggested that PA-49 located in the centre 
of PB1-binding pocket of PA (Fig. 8a and b). The important amino acid residues for PA–PB1 interface are con-
served in the virus strains tested (Fig. 8c), thereby suggesting the possible utility of PA-49 as an anti-influenza 
viral drug. To clarify the binding mode of PA-49, further analysis is needed based on structural analysis of the 
protein-compound complex by NMR and more accurate simulations including molecular dynamics simulation 
or fragment molecular orbital calculation.
Influenza A (H1N1)pdm09, H3N2 strain and two type B viruses are currently used for vaccine production, 
but it is likely that these viruses rapidly acquired resistance to oseltamivir and other NA inhibitors. The amino 
acid sequence of PA is also conserved in the oseltamivir-resistant clinical isolate of A(H1N1)pdm09 virus A/
Quebec/147365/2009(H1N1) strain (Fig. 8c), which has an H275Y mutation in NA33, thereby suggesting that 
PA-49 may be effective against oseltamivir-resistant clinical isolates. Recently, we reported that a novel influenza 
virus inhibitor NUD-1 can suppress influenza virus replication by targeting the influenza virus NP25, but it does 
not inhibit the replication of type B viruses. By contrast, the inhibitory activity of PA-49 was observed against type 
B virus with EC50 values less than 1 μM (Table 2).
Interestingly, many quinolinone compounds like PA-49 were selected by our screening analysis. Quinolinone 
is a major scaffold and useful pharmacophore in many drugs34, such as the bronchodilator procaterol35, 
antithrombotic agent cilostazol36 and antipsychotic agents aripiprazole37. In addition, a similar monomethyl 
quinolinone with a tetrazole group has been reported as a novel tyrosine phosphatase inhibitor38. Eleven hit 
compounds with anti-influenza activity (MIC values less than 20 μM) had quinolinone moiety (Fig. 1). Other 
hit compounds that do not have this moiety (PA-37, 58 and 107) showed weak binding properties to PA protein 
(Table 1). The important role of this moiety on the binding to PA should be elucidated.
According to our results, among the 99 commercially available compounds that we screened, 88 compounds 
had molecular weights more than 500 (ranging from 303.2–596.7, median = 532.7). Because the PA cavity for 
PB1 binding is relatively wide (Fig. 8a and b), it is possible that a fairly large molecule is necessary to specifically 
inhibit (with high affinity) PB1 binding to the PA cavity. It has been suggested that lead compounds with molec-
ular weights of less than 500 conform to Lipinski’s rule of five for drug-likeness39. Indeed, previously reported 
inhibitors targeting PA–PB1 interaction26, 40, 41 conform to this rule. However, recent advances in the development 
of protein–protein interaction inhibitors have demonstrated the suitability of medium-sized compounds with 
molecular weights of more than 50042. Recently, medium-sized compounds such as the antitumor agent eribulin 
(molecular weight = 729.9)43 and the BCL-2 inhibitor venetoclax (molecular weight = 868.4) for chronic lympho-
cytic leukaemia with 17p deletion44 have been approved.
In summary, we efficiently identified potent anti-influenza virus compounds that bind to PA by SBDD. PA-49 
could be a lead compound in the development of novel anti-influenza drugs. Optimisation of the structure of 
PA-49 to increase its anti-influenza activity and in vivo experiments are currently in progress. Focusing on the 
inhibition of viral protein–protein interactions will facilitate the development of antiviral drugs and our strategy 
using NUDE/DEGIMA system may be applicable in emergent drug screening for many other fatal RNA viruses.
Methods
In silico screening. In silico screening used an original docking simulation programme NUDE, which was 
designed to run on a GPU system24, 25. The algorithm employed by NUDE is based on evolutionary Monte Carlo 
(EMC) techniques45 and an empirical free energy model is used to evaluate the binding energy of a ligand. We 
used an original chemical compound library comprising approximately 600,000 compounds. For each com-
pound, a maximum of 50 conformations were generated using Open Babel software46, which were followed by 
energy minimisation with the GAFF force field47. In our docking simulation, the X-ray structure of influenza A 
www.nature.com/scientificreports/
9SCIENtIfIC RepORTS | 7: 9500  | DOI:10.1038/s41598-017-10021-w
virus PA was downloaded from the Protein Data Bank (PDB code: 2ZNL)15 as the receptor and a cubic space that 
included PB1-binding pocket of PA was employed as the search region. The docking simulation was performed 
using the NUDE/DEGIMA system.
Chemicals, cells, viruses and antibodies. Hit compounds were purchased from Namiki Syoji Co. Ltd 
(Tokyo, Japan) and dissolved in 100% dimethyl sulfoxide (DMSO). Benzbromarone was purchased from Tokyo 
Chemical Industry Co. Ltd (Tokyo, Japan) and dissolved in 100% DMSO. Oseltamivir phosphate purchased from 
F. Hoffmann-La Roche Ltd (Basel, Switzerland) was dissolved in phosphate-buffered saline (PBS) at a concentra-
tion of 10 mM. All of the compounds were maintained at −30 °C until use. Before performing the experiments, 
the compounds were diluted with Eagle’s minimum essential medium (MEM) supplemented with 1% 100× 
vitamin solution (MEM vitamin). HeLa cells were obtained from Dr Takujiro Homma (Nagasaki University, 
Japan) and maintained in Dulbecco’s modified Eagle’s medium (Sigma Aldrich, St Louis, MO) containing 10% 
fetal bovine serum (FBS). MDCK cells kindly donated by Dr Kyosuke Nagata (Tsukuba University, Japan) were 
grown in MEM supplemented with 5% FBS. These cells were maintained at 37 °C in an atmosphere of 5% CO2. 
Influenza viruses were prepared as described previously48 and stored at −80 °C. Anti-HA (GTX127357), -M1 
(GTX125928), -PA (GTX118991), -PB1 (GTX125923) and -NP (GTX125989) antibodies were purchased from 
GeneTex, Inc. (Irvine, CA). Anti-actin (A5060) antibody was purchased from Sigma Aldrich.
Plasmid construction and purification of recombinant PA protein. To construct a plasmid 
encoding the His-tagged C-terminal portion of PA (residues 239–716), total RNA was prepared from A/
WSN/33-infected MDCK cells. The RNA samples were reverse-transcribed using WSNPA1aa- pET15bNdeI 
(5′-CATATGGAAGATTTTGTGCGACAATGC-3′). PCR amplification was performed with the primer pair: 
WSNPA239aa- pET15bNdeI (5′-CATATGAACGGCTACATTGAGGGCAA-3′) and WSNPApET15bBamHIRev 
Figure 8. Binding mode of PA-49 compounds with influenza PA protein based on in silico calculations. (a,b) 
The crystal structure of the PA (grey)–PB1 (light blue) complex (PDB code: 2ZNL) and the binding structure 
of PA-49 from our docking simulations (pink) were overlaid: (a) side view and (b) top view. Side chains of 
PB1 protein are shown with stick representation. Hydrogen atoms are omitted for clarity. In order to obtain 
binding structure of PA–PA-49 complex, hydrogen atoms were added to the complex structure obtained from 
the docking simulation, followed by 1,000 steps of energy minimisation without any restraint using AMBER 
10 software package51. For minimisation, AMBER ff99SB52 and GAFF47 force fields were used for the protein 
and ligand, respectively. Colour code for atom: N (blue), O (red), S (yellow) and F (light green). (c) Amino 
acid sequence alignment of influenza virus PA protein (residues 601–716) including H1N1, H3N2 and H5N1 
subtypes. Residues that are required for PA–PB1 interface are labelled with yellow. Molecular structures in (a) 
and (b) were drawn using UCSF Chimera package53.
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(5′-GGATCCCTATCTCAATGCATGTGTGAGGAA-3′). The PCR products were subcloned into T-vector 
pMD19. The resultant plasmid was digested with NdeI and BamHI, and the fragment was subcloned into the 
NdeI-BamHI site of pET15b. To express the PA259–716 protein, the pET15b-PA259–716 plasmid was transformed into 
BL21(DE3) pLysS. The protein was induced at 23 °C by adding 0.5 mM IPTG at an OD600 value of 0.7 for 5.5 h. 
The bacteria were disrupted by sonication in buffer containing 20 mM Tris-HCl (pH 7.9), 150 mM NaCl, 25 mM 
imidazole, 500 mM urea, 10 mM 2-mercaptoethanol and proteinase inhibitor cocktail (No. 03969-21, Nacalai 
Tesque), before purification using His60 Ni Superflow™ Resin (Takara Bio Inc, Shiga, Japan). His–PA259–716 was 
eluted with the same buffer containing 100–400 mM imidazole. The purified protein was dialysed in dialysis 
buffer containing 20 mM Tris-HCl (pH 7.9), 150 mM NaCl, 20% glycerol and 5 mM DTT, and then stored at 
−80 °C until use. To construct pCAGGS-PA and pCAGGS-PB1 plasmids, the WSN PA and PB1 genes were 
inserted into the multiple cloning site of pCAGGS vector, respectively.
SPR analysis. Interactions between recombinant PA and compounds were evaluated by SPR using the 
Biacore T200 system (GE Healthcare UK Ltd, Buckinghamshire, UK), as described previously49 with some modi-
fications. Briefly, we immobilised the anti-PA antibody on a CM5 sensor chip (GE Healthcare, BR-100530) using 
an amine coupling kit (GE Healthcare, BR-1000-50) and running buffer (10 mM HEPES pH 7.4, 150 mM NaCl 
and 0.1% Tween 20 [Sigma Aldrich]). The amount of immobilised antibodies was ~8,000 RU. Next, the recom-
binant PA protein were loaded at a flow rate of 30 μL/min for capture by the antibodies on the sensor chip. The 
amount of PA protein captured reached ~2,000 RU. Compounds were analysed using the running buffer contain-
ing 5% DMSO. Data were corrected by using the anti-PA antibody immobilised sensor chip as a control.
EC50 and CC50 evaluations in CV assays. The anti-influenza virus activities of compounds were evaluated 
as described previously48 with some modifications. To evaluate the anti-influenza virus activities, MDCK cells 
were seeded into 96-well plates at a density of 3.0 × 104 cells/well in 100 μL of MEM containing 5% FBS, and then 
incubated overnight. Cells were washed with MEM vitamin and 100 μL of the serially diluted compound was 
then added. Cells were subsequently infected without (determination of CC50) or with (determination of EC50) 
100 μL of virus solution in MEM vitamin equivalent to 100 TCID50 for type A viruses or 30 TCID50 for B/Lee/40. 
The culture plates were incubated at 37 °C for 48 h. After incubation, cells were fixed with 70% EtOH and stained 
with 0.5% CV. After washing with water and air drying, the absorbance was measured at 560 nm using an Infinite 
M200 pro plate reader (Tecan Japan Co. Ltd, Kanagawa, Japan). To determine the yield of influenza virus, the 
supernatant from each well was collected and the virus yield was determined using the TCID50 assay. EC50 and 
CC50 values were calculated from the dose-response curve by linear regression analysis. The selectivity index was 
calculated by the formula: CC50/EC5050.
WST-1 assay. The WST-1 assay was performed as previously described29 with some modifications. Briefly, 
MDCK cells were seeded in 24-well plates at a density of 1.8 × 105 cells/well in MEM containing 5% FBS and 
incubated overnight. Cells were infected with the influenza virus in the presence of PA-49 and the culture plates 
were then incubated at 37 °C for 46 h. The medium was replaced with 0.6 mL of MEM vitamin containing 15 μL 
of Cell Proliferation Reagent WST-1 (Roche) and then incubated at 37 °C for 1 h. The absorbance was measured 
at 450–650 nm using the plate reader. The viability of cells was determined as described above. The plates were 
subsequently fixed and stained with CV as described above.
Statistical analysis. The results were expressed as the mean ± SD based on three independent experiments. 
The Student’s t-test was performed using GraphPad Prism software (Version 5.0.4, GraphPad Software, Inc, CA) 
to detect significant differences between the test samples and controls. P-values less than 0.05 were considered to 
indicate significant differences.
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